WO2019064807A1 - コラーゲンビトリゲル及びその精製物の製造方法並びに当該方法により得られたコラーゲンビトリゲル及びその精製物 - Google Patents
コラーゲンビトリゲル及びその精製物の製造方法並びに当該方法により得られたコラーゲンビトリゲル及びその精製物 Download PDFInfo
- Publication number
- WO2019064807A1 WO2019064807A1 PCT/JP2018/025846 JP2018025846W WO2019064807A1 WO 2019064807 A1 WO2019064807 A1 WO 2019064807A1 JP 2018025846 W JP2018025846 W JP 2018025846W WO 2019064807 A1 WO2019064807 A1 WO 2019064807A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- collagen
- vitrigel
- collagen vitrigel
- gelling agent
- purified
- Prior art date
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 380
- 108010035532 Collagen Proteins 0.000 title claims abstract description 380
- 229920001436 collagen Polymers 0.000 title claims abstract description 380
- 238000000034 method Methods 0.000 title claims abstract description 40
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 31
- 239000003349 gelling agent Substances 0.000 claims abstract description 175
- 239000000512 collagen gel Substances 0.000 claims abstract description 62
- 229910052806 inorganic carbonate Inorganic materials 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 238000001035 drying Methods 0.000 claims abstract description 15
- 229910001504 inorganic chloride Inorganic materials 0.000 claims abstract description 14
- 229910052816 inorganic phosphate Inorganic materials 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 238000011033 desalting Methods 0.000 claims abstract description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 60
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 60
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 38
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 32
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 30
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 30
- 239000011780 sodium chloride Substances 0.000 claims description 30
- 239000000463 material Substances 0.000 claims description 29
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 19
- 239000001110 calcium chloride Substances 0.000 claims description 19
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 19
- 235000011148 calcium chloride Nutrition 0.000 claims description 19
- 239000001103 potassium chloride Substances 0.000 claims description 19
- 235000011164 potassium chloride Nutrition 0.000 claims description 19
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 16
- 239000000306 component Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 9
- 230000036571 hydration Effects 0.000 claims description 7
- 238000006703 hydration reaction Methods 0.000 claims description 7
- 108010045569 atelocollagen Proteins 0.000 claims description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 239000012533 medium component Substances 0.000 claims description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 3
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims description 2
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 2
- 235000011009 potassium phosphates Nutrition 0.000 claims description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 235000011008 sodium phosphates Nutrition 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- 235000011181 potassium carbonates Nutrition 0.000 claims 1
- 239000012264 purified product Substances 0.000 abstract description 6
- 238000004132 cross linking Methods 0.000 abstract description 4
- 230000000887 hydrating effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 96
- 235000002639 sodium chloride Nutrition 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 239000008223 sterile water Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 24
- 239000002953 phosphate buffered saline Substances 0.000 description 23
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 18
- 238000004925 denaturation Methods 0.000 description 16
- 230000036425 denaturation Effects 0.000 description 16
- 239000000499 gel Substances 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 14
- 239000008279 sol Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 239000012528 membrane Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- 238000001879 gelation Methods 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000007605 air drying Methods 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000004017 vitrification Methods 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 150000002484 inorganic compounds Chemical class 0.000 description 3
- 229910010272 inorganic material Inorganic materials 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- -1 inorganic carbonates Chemical class 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- LPLLVINFLBSFRP-UHFFFAOYSA-N 2-methylamino-1-phenylpropan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1 LPLLVINFLBSFRP-UHFFFAOYSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000012432 Collagen Type V Human genes 0.000 description 1
- 108010022514 Collagen Type V Proteins 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 241000132539 Cosmos Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 102000013373 fibrillar collagen Human genes 0.000 description 1
- 108060002894 fibrillar collagen Proteins 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
Definitions
- the present invention relates to a method for producing collagen vitrigel and its purified product. More specifically, the present invention relates to collagen vitrigel usable for medical use etc., fibrillizing collagen, purified collagen vitrigel and methods for producing them.
- Collagen is one of the proteins present in vivo. In humans, it accounts for about 30% of the whole-body protein and is particularly abundant in skin, bone, cartilage, tendon and blood vessel wall.
- the molecular weight of collagen is about 300,000, forming a triple helix structure consisting of three polypeptide chains with a molecular weight of about 100,000.
- This collagen has a large number of molecular species that differ in amino acid sequence order and amino acid composition ratio depending on the animal from which they are derived and their tissues.
- Collagen plays a role as a scaffold for cells as an extracellular matrix in vivo and is known to affect proliferation, differentiation and morphogenesis, and has been used as a carrier for cell culture since ancient times, and in recent years it has been used as a living graft. It is also applied as a material.
- various culture petri dishes and flasks coated with a collagen coating are commercially available as a cell culture carrier, and an embedded culture method is known in which cells are dispersed in collagen gel and cultured.
- a biograft material there are a collagen gel material carrying cells, an injectable gel which is transplanted in a solution state and gelated in vivo, and a material obtained by drying collagen gel and processing it into a membrane or sponge.
- Non-Patent Document 1 discloses a cartilage graft material
- Patent Document 1 discloses a gelling material for in-vivo injection
- Patent Document 2 discloses an artificial skin material and the like.
- shape of the biograft material which consists of collagens varies, there are many materials processed and shape
- Such a collagen gel can be obtained by placing a collagen solution under physiological salt concentration, hydrogen ion concentration and temperature conditions, and as a gelling agent therefor, various cell cultures are generally used.
- a solution, a saline solution, or a buffer solution having a buffer capacity in the neutral region is used.
- collagen vitrigel is a novel collagen material expected to be applied as a biograft material.
- “Vitrigel (registered trademark) (registered trademark) 5602094" is a new scientific term named by Takezawa et al., Obtained by vitrification of a hydrogel such as conventional extracellular matrix and rehydration. It is defined as a gel in a stable state (non-patent document 2).
- Collagen vitrigel which is formed from collagen which is one of the extracellular matrix, consists of high density collagen fibers.
- a thin film using this collagen vitrigel is characterized by being thinner and higher in strength than conventional plate-like collagen gel materials, and its application as a biograft material is expected, for example, in Non-Patent Document 3
- a cartilage graft material consisting of a collagen vitrigel thin film starting from pig skin-derived atelocollagen.
- a dried collagen vitrigel thin film starting from bovine skin-derived native collagen has already been commercialized as a substrate for cell culture (Kanto Chemical Co., Ltd. # ad-MED Vitrigel (trade name)).
- Non-Patent Document 4 discloses a method of preparing collagen vitrigel from pig skin-derived atelocollagen using DMEM to which HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) is added as a gelling agent. There is.
- HEPES 4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid
- the method of obtaining collagen gel by using DMEM as a gelling agent is a preparation method conventionally used in the embedded culture method of in vitro test, it is not preferable as a preparation method of a biograft material. Because DMEM contains more than 30 compounds, only a few of them are involved in collagen gelation, and DMEM is used to prepare collagen vitrigel as a biograft material. For this reason, it is necessary to confirm the safety of more than 30 compounds and to set the residual tolerance limit, which causes a great burden on the manufacturer.
- the said nonpatent literature 4 is disclosing the collagen vitrigel obtained using the phosphate buffer solution (PBS) which added HEPES as a gelatinizer.
- PBS phosphate buffer solution
- HEPES HEPES
- a method of compensating for the low strength of collagen vitrigel a method of enhancing film strength by chemical crosslinking by addition of a crosslinking agent or physical crosslinking by irradiation of ultraviolet rays or gamma rays is known as a method of compensating for the low strength of collagen vitrigel.
- cross-linking with a compound may cause biotoxicity of the added compound, and irradiation of ultraviolet light and gamma rays may cause denaturation of collagen, so these cross-linking treatments are not performed. Is desirable.
- a compound with high safety is selected as a component of the gelling agent, and while the composition is as simple as possible, development of a method capable of finally preparing a collagen vitrigel having sufficient strength Is required.
- Patent No. 6071468 gazette Patent No. 4674211
- An object of the present invention is to develop a gelling agent having a simple composition consisting only of a compound having high safety to the living body in consideration of the above situation, and from collagen, the membrane strength is high without crosslinking treatment, and industrial Manufacturing a collagen vitrigel which is easy to manufacture, easy to process, and easy to handle, and its purified product.
- an object of the present invention is a collagen vitrigel obtained by fibrillating collagen, a purified product of the same, and a method for producing the same, using a gelling agent of a simple composition consisting only of a compound highly safe to the living body.
- the inventors of the present invention conducted intensive studies on a gelling agent used for producing a collagen gel, and as a result, at least one compound of inorganic carbonates such as inorganic carbonates and inorganic hydrogen carbonates, and inorganic chlorides and inorganics
- a solution containing at least one compound of phosphate as a gelling agent
- collagen gel can be produced without using conventional medium components and organic buffer components, and obtained
- the collagen gel was found to be highly safe because it contains no components other than the above-mentioned inorganic components.
- the present inventors have found that collagen vitrigel derived from this collagen gel and purified products thereof have high membrane strength, are easy to manufacture and process, and are easy to handle.
- the present invention gelates collagen with a gelling agent containing an inorganic carbonate and a compound selected from the group consisting of an inorganic chloride and an inorganic phosphate, and then drying the obtained collagen gel. It is a method of producing collagen vitrigel characterized by vitrifying and further subjecting it to hydration treatment.
- the present invention is further characterized in that purified collagen vitrigel (hydrated form) characterized by desalting and equilibrating collagen vitrigel prepared by the above-mentioned production method, and further drying and revitrifying it. It is a manufacturing method of purified collagen vitrigel (dried form) to be
- the present invention is a collagen vitrigel obtained by the above method and a purified collagen vitrigel.
- the inorganic salts are used without mixing the organic compound such as the medium component and the organic type buffer component into the gelling agent of collagen, the remaining component in the gel produced is small, and the composition thereof Is clear and a collagen gel is obtained which is less prone to problems caused by contaminants.
- collagen vitrigel produced from this collagen gel and purified collagen vitrigel derived therefrom are highly safe for the living body, and can be advantageously used, for example, in medical applications including living transplantation. is there.
- collagen vitrigel means rehydrated collagen dry body (collagen xerogel) which has been vitrified by drying collagen gel.
- purified collagen vitrigel means one obtained by equilibrating this collagen vitrigel after desalting treatment, one obtained by further drying and revitrifying it, and its rehydrate.
- the collagen vitrigel of the present invention is prepared by mixing collagen with an aqueous solution containing an inorganic carbonate and a compound (inorganic salt) selected from the group consisting of an inorganic chloride and an inorganic phosphate, Then, the collagen gel dried obtained by vitrification by drying is obtained by further hydration.
- collagen vitrigel is produced as follows. That is, first, an aqueous solution containing a collagen solution, the inorganic carbonate salt, and a compound selected from the group consisting of inorganic chloride and inorganic phosphate (hereinafter sometimes abbreviated as "gelling agent") A collagen sol is obtained by mixing, and the collagen sol is heated to be fibrillated to give a collagen gel. Then, this is dried and vitrified to obtain a collagen vitrigel by hydration treatment of the collagen gel dried product.
- gelling agent a compound selected from the group consisting of inorganic chloride and inorganic phosphate
- purified collagen vitrigel can be obtained by further desalting (washing) and equilibrating the collagen vitrigel obtained as described above, and further drying and re-vitrifying it, if necessary, again. It is obtained by hydration.
- the collagen used in the present invention is not particularly limited for the animal species from which it is derived, and various types can be used.
- mammalian origin collagen for example, bovine origin collagen, pig origin collagen, goat origin collagen, sheep origin collagen, or monkey origin collagen
- avian origin collagen for example, chicken origin collagen, geese origin collagen, duck
- Origin collagen or ostrich origin collagen fish origin collagen (eg salmon origin collagen, Thailand origin collagen, tuna origin collagen, tilapia origin collagen or shark origin collagen) reptile origin collagen (eg crocodile origin collagen) amphibian origin Collagen (eg, frog-derived collagen), invertebrate-derived collagen (eg, jellyfish-derived collagen)
- part from which the said collagen is derived For example, skin, a bone, a cartilage, a muscle, or an eyelid can be mentioned.
- collagen which is preferably used is collagen which is not denatured and stable at 37 ° C. or less which is a human living body temperature.
- the denaturation temperature of collagen is related to the habitat of the organism from which it is derived, and collagen of aquatic organisms such as fish has a denaturation temperature in the low temperature zone compared to that of human. Therefore, it is preferable to use terrestrial living organism-derived collagen in which the denaturation temperature of collagen is close to that of human being, and in terms of industrially stable supply, it is preferable to obtain collagen from livestock animals.
- livestock animals cattle and pigs are mentioned, but cattle are not preferable because they have a risk of holding pathogens such as BSE (bovine spongiform encephalopathy), and pigs are preferable.
- the collagen used in the present invention is not limited as to molecular structure as long as it is fibrillar collagen, and as molecular species (type), for example, type I collagen, type II collagen, type III collagen, or Examples include type V collagen.
- type I collagen, type II collagen, type III collagen, or Examples include type V collagen.
- collagen composed mainly of type I collagen or type III collagen is preferable from the viewpoint of high industrial yield and relatively low cost and stable supply.
- telopeptide non-helical structure region present at the end of the collagen molecule has antigenicity, it is more preferable to use atelocollagen in which this telopeptide is removed (atherated) by enzyme treatment.
- the collagen is preferably used in the form of a solution dissolved in a solvent such as water for gelation, and more preferably an acid solubilized collagen solution having a pH of 2.0 to 6.0. If the pH is lower than 2.0, there is a possibility of hydrolysis of collagen molecules, and if the pH is higher than 6.0, collagen may not be sufficiently solubilized, which is not preferable.
- the final concentration after mixing with the gelling agent is preferably in the range of 0.05 w / v% to 5.0 w / v%, and more preferably 0.2 w / v% to 2.%. It is in the range of 0 w / v%.
- the gelling agent used for gelation of collagen is a compound selected from the group consisting of inorganic carbonates (inorganic carbonates, inorganic bicarbonates), inorganic chlorides and inorganic phosphates ( Hereinafter, it is an aqueous solution containing "inorganic salts" (it may abbreviate abbreviated).
- the inorganic carbonate used as a component of the gelling agent is not limited as to molecular structure as long as it is easily soluble in water, and, for example, inorganic carbonates such as sodium carbonate and potassium carbonate Salts and inorganic hydrogen carbonates such as sodium hydrogen carbonate and potassium hydrogen carbonate can be used.
- inorganic salts used as another component of the gelling agent belong to inorganic chlorides and inorganic phosphates, and as long as they are easily soluble in water, the molecular structure is not limited, and for example, , Inorganic chlorides such as sodium chloride, potassium chloride, magnesium chloride and calcium chloride, sodium phosphate, potassium phosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate Inorganic phosphoric acids such as calcium dihydrogen phosphate can be used.
- Inorganic chlorides such as sodium chloride, potassium chloride, magnesium chloride and calcium chloride
- sodium phosphate, potassium phosphate disodium hydrogen phosphate, dipotassium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate
- Inorganic phosphoric acids such as calcium dihydrogen phosphate can be used.
- Types of inorganic carbonates and inorganic salts (inorganic chloride or inorganic phosphate) or combinations thereof in this gelling agent can cause collagen fibrosis (self-assembly) when mixed with collagen solution
- the solution (collagen sol) after mixing the gelling agent and the collagen solution preferably has a pH of 6.2 to 9.8 at 25 ° C., and is 6.8 to 9.0. More preferable.
- the concentration of inorganic carbonates and inorganic salts in the gelling agent the ionic strength in the collagen sol is preferably in the range of 0.07 to 0.22, preferably 0.07 to 0.18. It is more preferable to be in the range.
- a collagen sol prepared by mixing a gelling agent and a collagen solution is heated to fibrillate collagen to form a collagen gel.
- the temperature at that time is the denaturation temperature of the collagen used. It is preferable to determine on the basis of Collagen fibrosis is triggered near the denaturation temperature of collagen, and fibrosis is not triggered at temperatures well below the denaturation temperature. That is, it is preferable that the temperature is ⁇ 20 ° C. or higher with respect to the denaturation temperature, and the range is equal to or lower than the denaturation temperature. For example, since the denaturation temperature of pig-derived collagen is 41 ° C., the range of 21 ° C. to 41 ° C. is preferable.
- the collagen gel obtained as described above is then dried and vitrified to give a collagen gel dry body (collagen xerogel).
- This "vitrification” is, for example, by drying a hydrogel of a heat-denatured protein such as chicken egg protein (white body) and removing water sufficiently to form a hard, highly transparent glass-like substance. It means the phenomenon to convert (Takushi Eisei, "Edible eyeballs from fish", Nature , 1990, Vol 345, p. 298-299).
- air drying is preferably used as a drying method for vitrifying collagen gel, and the temperature thereof is preferably equal to or less than the denaturation temperature of collagen.
- a collagen gel is allowed to stand for 2 days under conditions of temperature and humidity of 10 ° C. and about 40% rh to vitrify the collagen gel. It is preferred to do.
- the dried collagen gel thus obtained can then be rehydrated to form collagen vitrigel.
- the solution used for rehydration of the dried collagen gel contains a component contained in the gelling agent of the present invention, and the pH range is neutral (for example, saline, phosphate buffer, purified water, etc.
- aqueous solution having a pH of about 6.0 to 8.0 can be mentioned.
- the solution used for this rehydration does not need to have the same composition and concentration as the gelling agent at the time of collagen gel production, and is not limited thereto.
- the temperature of the aqueous solution used for hydration is preferably a temperature significantly below the denaturation temperature of the collagen to be used, and is preferably -20 ° C. or less with respect to the denaturation temperature.
- collagen vitrigel is prepared as a hydrate.
- This collagen vitrigel has high strength of itself, is industrially and mechanically easy to manufacture and process, and is easy to handle.
- this collagen vitrigel is conventionally used only as a gelling agent used in its production process and as an ingredient of rehydrating agents, only inorganic compounds such as inorganic carbonates, inorganic chlorides and inorganic phosphates. Since such medium components and organic substances are not used, they can be used, for example, as a medically safe collagen gel biogel having high safety.
- the collagen vitrigel may be further subjected to a desalting treatment, an equilibration treatment, and then dried to form a purified collagen vitrigel (dry matter).
- the inorganic compound contained in the gelling agent to be used may be concentrated by drying and precipitated as crystals if it is included. Since crystals are deposited unevenly on the surface of collagen vitrigel dry body, the appearance is impaired and there may be a problem in product uniformity.
- the desalting treatment carried out here is carried out by immersing collagen vitrigel in an aqueous solution in which the pH is in a neutral range (for example, about pH 6.0 to 8.0), but in D-PBS (-) It is preferable to carry out by immersion. Specifically, for example, the dried collagen gel is soaked in 1 mL or more of D-PBS (-) per 10 mg to be hydrated to form collagen vitrigel, and then D-PBS (-) around collagen vitrigel is used. Desalting of collagen vitrigel and equilibration with D-PBS (-) can be carried out by removing and immersing in D-PBS (-) two more times.
- the temperature of the aqueous solution in this operation is preferably a temperature greatly below the denaturation temperature of the collagen to be used, and is preferably ⁇ 20 ° C. or less with respect to the denaturation temperature.
- air drying as the drying for revitrification of the purified collagen vitrigel (hydrated form), and the temperature thereof is preferably equal to or less than the denaturation temperature of collagen. More specifically, it is preferable to use a constant temperature and humidity chamber for air drying, for example, leaving purified collagen vitrigel (hydrated body) in a temperature and humidity condition of 10 ° C and a constant temperature and humidity chamber of 40% rh for 1 day It is preferable to carry out drying.
- the collagen vitrigel and the purified collagen vitrigel prepared by the above-described method, as described above, have sufficient strength per se and high safety, and therefore, the cell carrier for regenerative medicine especially for medical use.
- the shape can also be processed into arbitrary shapes, for example, plate shape, film shape, rod shape, thread shape, cylindrical shape, tubular shape, bag shape etc. according to the use.
- This collagen gel was dried for 2 days in a constant temperature and humidity chamber (temperature and humidity conditions 10 ° C., 40% rh) for vitrification to obtain a collagen gel dried body. Furthermore, this collagen gel dried body was hydrated by immersion in 1 mL of D-PBS ( ⁇ ) per 10 mg to obtain collagen vitrigel.
- Excess salt is removed by washing the above collagen vitrigel twice with D-PBS (-) to equilibrate the collagen vitrigel to D-PBS (-), and then the temperature and humidity chamber (temperature and humidity again) It was dried at 10 ° C. and 40% rh) for 2 days to obtain a purified collagen vitrigel (dry matter).
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- Collagen vitrigel and purified collagen vitrigel (dry matter) were prepared in the same manner as in Example 1 except that the gelling agent was changed to the above gelling agent.
- the collagen gel was dried by a constant temperature and humidity oven and vitrified to obtain a dried collagen gel. Furthermore, this collagen gel dried body was hydrated by immersion in 1 mL of D-PBS ( ⁇ ) per 10 mg to obtain collagen vitrigel. After washing collagen vitrigel twice with D-PBS (-) to remove excess salts and other components, the collagen vitrigel is equilibrated to D-PBS (-), dried again, The corresponding dried form of vitrigel was obtained.
- PH measurement The pH was measured on the collagen gel before gelation of Examples 1 to 29 and Comparative Examples 1 to 10. The pH was measured by placing 0.5 mL of each collagen sol into a measuring electrode dish of a pH meter (Horiba, Ltd. #LAQUAtwin AS-712) and measuring the pH.
- Example 1 Examples 1 to 3, Example 8, Example 10, Example 12, Example 18, Example 23 to 25, Example 27, Example 29 to 31 and Comparative Example 1
- Purified Collagen Vitrigel Water Hydrate Film strength was measured.
- the membrane strength of the purified collagen vitrigel (hydrate) was measured by the following method. That is, purified collagen vitrigel (dry matter) having a diameter of 34.8 mm was immersed in 8 ml of D-PBS (-) and rehydrated for 1 hour. The purified collagen vitrigel (hydrated form) obtained by hydration was sandwiched and fixed between two 50 mm diameter acrylic plates with a 5 mm diameter hole in the center.
- a stainless steel needle with a diameter of 1.0 mm is vertically pierced at a speed of 3.0 mm / min against the membrane fixed through the hole of 5 mm in diameter, and the needle penetrates the purified collagen vitrigel (hydrated body)
- the maximum stress (N) up to the end was measured using a small bench test machine (Shimadzu Corporation # EZ-SX, load cell maximum load 5 N). The measurement was carried out at three places for each purified collagen vitrigel (hydrate), and the average value was taken as the maximum stress (N). This operation was performed on three purified collagen vitrigels (hydrates), and the average value of the three maximum stresses was taken as the membrane strength (N).
- the purified collagen vitrigel obtained by the method of the present invention has sufficient membrane strength and is substantially free of residual components other than inorganic salts, and is biologically safe. It was highly practical and practical.
- collagen vitrigel and its purified product with high biosafety can be easily obtained at low cost.
- the obtained collagen vitrigel and purified collagen vitrigel have sufficient membrane strength, are industrially and mechanically easy to manufacture and process, are easy to handle, and have high safety.
- the biograft material of the present invention is useful as, for example, a cell carrier for regenerative medicine, a wound covering material, an artificial skin, an adhesion preventing material and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
ブタ皮膚由来アテロコラーゲン(日本ハム(株)#NMPコラーゲンPS)2gを滅菌水200mLに溶解し、1w/v%コラーゲン溶液を調製した。
リン酸緩衝生理食塩水(D‐PBS(-);和光純薬工業(株)#045‐29795)500mLに炭酸水素ナトリウム(和光純薬工業(株)#191‐01305)1.85gを加えて溶解しゲル化剤とした。
50mL容量のコニカルチューブ(コーニング#352070)に、ゲル化剤と1w/v%コラーゲン溶液をそれぞれ20mL採り、均一に混和し、これをコラーゲンゾルとした。コラーゲンゾルの調製は氷冷下で行った。次いで、ポリスチレン角型シャーレ(アズワン(株)#D210‐16)にアクリル円筒鋳型((株)コスモスビード、外径38.8mm×内径34.8mm×高さ30.0mm)を置き、この鋳型内にコラーゲンゾル10mLを充填した。37℃の恒温機内に2時間静置してコラーゲンを線維化させ、コラーゲンゲルを得た。
塩化ナトリウム(和光純薬工業(株)#191‐01665)3.21g、リン酸二水素カリウム(和光純薬工業(株)#169‐04245)3.40g、炭酸水素ナトリウム1.85gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、炭酸水素ナトリウム1.85gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
リン酸緩衝生理食塩水500mLに炭酸水素ナトリウム0.42gを加えて溶解しゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
リン酸緩衝生理食塩水500mLに炭酸水素ナトリウム0.84gを加えて溶解しゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
リン酸緩衝生理食塩水500mLに炭酸水素ナトリウム2.27gを加えて溶解しゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
リン酸緩衝生理食塩水500mLに炭酸水素ナトリウム0.42gと炭酸ナトリウム(和光純薬工業(株)#196‐01595)0.53gを加えて溶解しゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
リン酸緩衝生理食塩水500mLに炭酸水素ナトリウム1.85gと炭酸ナトリウム0.53gを加えて溶解しゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
リン酸緩衝生理食塩水500mLに炭酸水素ナトリウム2.94gを加えて溶解しゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、炭酸水素ナトリウム0.46gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、炭酸水素ナトリウム0.84gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、炭酸水素ナトリウム2.52gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、炭酸水素ナトリウム2.94gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、炭酸水素ナトリウム3.36gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、塩化カリウム(和光純薬工業(株)#163‐03545)0.10g、塩化カルシウム(和光純薬工業(株)#039‐00475)0.10g、リン酸二水素ナトリウム一水和物(Millipore#10049-21-5)0.07g、炭酸水素ナトリウム0.42g、炭酸ナトリウム0.53gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、塩化カリウム0.10g、塩化カルシウム0.10g、リン酸二水素ナトリウム一水和物0.07g、炭酸水素ナトリウム1.85g、炭酸ナトリウム1.59gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム1.17g、炭酸水素ナトリウム4.62gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、塩化カリウム0.10g、塩化カルシウム0.10g、リン酸二水素ナトリウム一水和物0.07g、炭酸水素ナトリウム0.42gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、塩化カリウム0.10g、塩化カルシウム0.10g、リン酸二水素ナトリウム一水和物0.07g、炭酸水素ナトリウム0.84gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、塩化カリウム0.10g、塩化カルシウム0.10g、リン酸二水素ナトリウム一水和物0.07g、炭酸水素ナトリウム1.68gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、塩化カリウム0.10g、塩化カルシウム0.10g、リン酸二水素ナトリウム一水和物0.07g、炭酸水素ナトリウム2.52gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、塩化カリウム0.10g、塩化カルシウム0.10g、リン酸二水素ナトリウム一水和物0.07g、炭酸水素ナトリウム3.36gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、塩化カリウム0.10g、塩化カルシウム0.10g、リン酸二水素ナトリウム一水和物0.07g、炭酸水素ナトリウム4.20gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、塩化カリウム0.10g、塩化カルシウム0.10g、リン酸二水素ナトリウム一水和物0.07g、炭酸ナトリウム0.53gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、塩化カリウム0.10g、塩化カルシウム0.10g、リン酸二水素ナトリウム一水和物0.07g、炭酸ナトリウム1.06gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、塩化カリウム0.10g、塩化カルシウム0.10g、リン酸二水素ナトリウム一水和物0.07g、炭酸水素ナトリウム0.84g、炭酸ナトリウム0.27gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、塩化カリウム0.10g、塩化カルシウム0.10g、リン酸二水素ナトリウム一水和物0.07g、炭酸水素ナトリウム0.84g、炭酸ナトリウム0.53gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、塩化カリウム0.10g、塩化カルシウム0.10g、リン酸二水素ナトリウム一水和物0.07g、炭酸水素ナトリウム0.84g、炭酸ナトリウム1.06gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
リン酸緩衝生理食塩水500mLに炭酸水素ナトリウム0.21gを加えて溶解しゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
ハンクス緩衝塩類溶液(HBSS(-);和光純薬工業(株)#085‐09355)500mLに炭酸ナトリウム0.85gを加えて溶解しゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
塩化ナトリウム3.21g、塩化カリウム0.10g、塩化カルシウム0.10g、リン酸二水素ナトリウム一水和物0.07g、炭酸ナトリウム0.27gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1と同様な方法でコラーゲンビトリゲル及び精製コラーゲンビトリゲル(乾燥体)を調製した。
ダルベッコ改変イーグル培地(DMEM)490mLに1mol/L HEPES(4-(2-ヒドロキシエチル)-1-ピペラジンエタンスルホン酸);Thermo Fisher Scientific#15630‐080)10mLを加え、均一に混和し、これをゲル化剤とした。
50mL容量のコニカルチューブに上記ゲル化剤と実施例1の1w/v%コラーゲン溶液をそれぞれ20mL採り、均一に混和し、これをコラーゲンゾルとした。コラーゲンゾルの調製は氷冷下で行った。次いでポリスチレン角型シャーレにアクリル円筒鋳型を置き、この鋳型内にコラーゲンゾル10mLを充填した。37℃の炭酸ガスインキュベーター(CO2 5%)内に2時間静置してコラーゲンを線維化させ、コラーゲンゲルを得た。
ゲル化剤をD‐PBS(-)に変更した以外は、実施例1の方法でコラーゲンビトリゲルの調製を試みた。しかし、一度はゲル化したコラーゲンゲルがその後の工程において溶解、ゾル化したためにコラーゲンゲル乾燥体として回収できず、コラーゲンビトリゲルを得られなかった。
塩化ナトリウム8.77gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1の方法でコラーゲンビトリゲルの調製を試みた。しかし、一度はゲル化したコラーゲンゲルがその後の工程において溶解、ゾル化したためにコラーゲンゲル乾燥体として回収できず、コラーゲンビトリゲルを得られなかった。
塩化ナトリウム1.75g、リン酸二水素ナトリウム一水和物0.14g、リン酸水素二ナトリウム(和光純薬工業(株)#197‐02865)1.35gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1の方法でコラーゲンビトリゲルの調製を試みた。しかし、一度はゲル化したコラーゲンゲルがその後の工程において溶解、ゾル化したためにコラーゲンゲル乾燥体として回収できず、コラーゲンビトリゲルを得られなかった。
ゲル化剤をHBSS(-)に変更した以外は、実施例1の方法でコラーゲンビトリゲルの調製を試みた。しかし、コラーゲンがゲル化しなかったためにコラーゲンゲルを得られず、コラーゲンビトリゲルを得られなかった。
HBSS(-)500mLに炭酸ナトリウム2.12gを加えて溶解しゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1の方法でコラーゲンビトリゲルの調製を試みた。しかし、コラーゲンがゲル化しなかったためにコラーゲンゲルを得られず、コラーゲンビトリゲルを得られなかった。
HBSS(-)500mLに炭酸ナトリウム4.24gを加えて溶解しゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1の方法でコラーゲンビトリゲルの調製を試みた。しかし、コラーゲンがゲル化しなかったためにコラーゲンゲルを得られず、コラーゲンビトリゲルを得られなかった。
塩化ナトリウム3.21g、塩化カリウム0.10g、塩化カルシウム0.10g、リン酸二水素ナトリウム一水和物0.07gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1の方法でコラーゲンビトリゲルの調製を試みた。しかし、コラーゲンがゲル化しなかったためにコラーゲンゲルを得られず、コラーゲンビトリゲルを得られなかった。
塩化ナトリウム3.21g、塩化カリウム0.10g、塩化カルシウム0.10g、リン酸二水素ナトリウム一水和物0.07g、炭酸水素ナトリウム0.21gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1の方法でコラーゲンビトリゲルの調製を試みた。しかし、コラーゲンがゲル化しなかったためにコラーゲンゲルを得られず、コラーゲンビトリゲルを得られなかった。
塩化ナトリウム3.21g、塩化カリウム0.10g、塩化カルシウム0.10g、リン酸二水素ナトリウム一水和物0.07g、炭酸ナトリウム2.12gを採り、滅菌水500mLに溶解し、これをゲル化剤とした。
ゲル化剤を上記ゲル化剤に変更した以外は、実施例1の方法でコラーゲンビトリゲルの調製を試みた。しかし、コラーゲンがゲル化しなかったためにコラーゲンゲルを得られず、コラーゲンビトリゲルを得られなかった。
実施例1~31及び比較例1~10のコラーゲンゾルに含まれる無機化合物の濃度とそのイオン強度及びpH、実施例1~3、実施例8、実施例10、実施例12、実施例18、実施例23~25、実施例27、実施例29~31及び比較例1の精製コラーゲンビトリゲル(水和体)の膜強度測定を下記方法により行った。この結果を表1~表7に示す。
pHは、実施例1~29及び比較例1~10の、ゲル化前のコラーゲンゾルについて測定した。pH測定は、各コラーゲンゾル0.5mLをpHメーター((株)堀場製作所#LAQUAtwin AS-712)の測定電極皿に入れ、そのpHを測定することで行った。
コラーゲンゾルに含まれる化合物(コラーゲンを除く)のイオン種A、B、C...それぞれのモル濃度(mol/L)をmA、mB、mC...、それぞれの電荷数をZA、ZB、ZC...とするとき、そのコラーゲンゾルのイオン強度Iは下式で定義される。
実施例1~3、実施例8、実施例10、実施例12、実施例18、実施例23~25、実施例27、実施例29~31及び比較例1の精製コラーゲンビトリゲル(水和体)の膜強度を測定した。精製コラーゲンビトリゲル(水和体)の膜強度は以下の方法により測定した。すなわち、直径34.8mmの精製コラーゲンビトリゲル(乾燥体)を8mlのD‐PBS(-)に浸漬して1時間再水和した。水和により得られた精製コラーゲンビトリゲル(水和体)を中央に直径5mmの穴の開いた直径50mmのアクリル板2枚で挟み固定した。この直径5mmの穴から覗く固定された膜に対して、直径1.0mmのステンレス製針を垂直に、3.0mm/minの速度で突き刺し、針が精製コラーゲンビトリゲル(水和体)を貫通するまでの最大応力(N)を小型卓上試験機((株)島津製作所#EZ‐SX、ロードセル最大荷重5N)を用いて測定した。精製コラーゲンビトリゲル(水和体)1つにつき3ヵ所について測定を行い、その平均値を最大応力(N)とした。この操作を3つの精製コラーゲンビトリゲル(水和体)に対して行い、3つの最大応力の平均値を膜強度(N)とした。
Claims (26)
- コラーゲンを、無機炭酸塩類と、無機塩化物および無機リン酸塩よりなる群から選ばれる化合物とを含有するゲル化剤でゲル化し、次いで得られたコラーゲンゲルをガラス化し、更にこれを水和処理に付すことを特徴とするコラーゲンビトリゲルの製造方法。
- 前記コラーゲンがブタ皮膚由来アテロコラーゲンである、請求項1に記載のコラーゲンビトリゲルの製造方法。
- コラーゲンとゲル化剤の混合物の25℃におけるpHが、6.2~9.8である、請求項1または2記載のコラーゲンビトリゲルの製造方法。
- コラーゲンとゲル化剤の混合物中に含まれる化合物のイオン強度が、0.07~0.22である、請求項1ないし3のいずれかの項記載のコラーゲンビトリゲルの製造方法。
- 前記無機炭酸塩類が無機炭酸塩または無機炭酸水素塩である請求項1ないし4のいずれかの項記載のコラーゲンビトリゲルの製造方法。
- 前記無機炭酸塩が、炭酸ナトリウムまたは炭酸カリウムである、請求項5記載のコラーゲンビトリゲルの製造方法。
- 前記無機炭酸水素塩が、炭酸水素ナトリウムまたは炭酸水素カリウムである、請求項5または6記載のコラーゲンビトリゲルの製造方法。
- 前記無機塩化物が、塩化ナトリウム、塩化カリウム、塩化マグネシウムおよび塩化カルシウムよりなる群から選ばれる1種以上である、請求項1ないし7のいずれかの項記載のコラーゲンビトリゲルの製造方法。
- 前記無機リン酸塩が、リン酸ナトリウム、リン酸カリウム、リン酸水素二ナトリウム、リン酸水素二カリウム、リン酸二水素ナトリウム、リン酸二水素カリウムおよびリン酸二水素カルシウムよりなる群から選ばれる1種以上である、請求項1ないし8のいずれかの項に記載のコラーゲンビトリゲル製造方法。
- 前記ゲル化剤が、培地成分および有機緩衝剤成分由来の有機成分を含まないものである請求項1ないし9のいずれかの項記載のコラーゲンビトリゲル製造方法。
- 請求項1ないし10のいずれかの項記載の製造方法で調製したコラーゲンビトリゲルを、脱塩、平衡化することを特徴とする精製コラーゲンビトリゲル水和体の製造方法。
- 請求項11の製造方法で調製した精製コラーゲンビトリゲル水和体を、更に乾燥して再ガラス化することを特徴とする精製コラーゲンビトリゲル乾燥体の製造方法。
- 請求項12の製造方法で調製した精製コラーゲンビトリゲル乾燥体を、更に再水和することを特徴とする精製コラーゲンビトリゲル水和体の製造方法。
- 請求項1ないし10のいずれかの項記載の方法により得られるコラーゲンビトリゲル。
- 少なくとも請求項14記載のコラーゲンビトリゲルを含む生体移植材料。
- 使用前に細胞を担持しないものである、請求項15に記載の生体移植材料。
- 少なくとも請求項14記載のコラーゲンビトリゲルを含む医療用人工皮膚。
- 請求項第11項または請求項第13項のいずれかの項記載の方法により得られる精製コラーゲンビトリゲル水和体。
- 少なくとも請求項18記載の精製コラーゲンビトリゲル水和物を含む生体移植材料。
- 使用前に細胞を担持しないものである、請求項19に記載の生体移植材料。
- 少なくとも請求項18記載の精製コラーゲンビトリゲル水和物を含む医療用人工皮膚。
- 請求項第12項記載の方法により得られる精製コラーゲンビトリゲル乾燥体。
- 少なくとも請求項22記載の精製コラーゲンビトリゲル乾燥体を含む生体移植材料。
- 使用前に細胞を担持しないものである、請求項23に記載の生体移植材料。
- 少なくとも請求項22記載の精製コラーゲンビトリゲル乾燥体を含む医療用人工皮膚。
- コラーゲンを、無機炭酸塩類と、無機塩化物および無機リン酸塩からなる群より選ばれる化合物とを含有するゲル化剤でゲル化し、次いで得られたコラーゲンゲルをガラス化することにより得られるコラーゲンゲル乾燥体。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020207010563A KR20200066314A (ko) | 2017-09-29 | 2018-07-09 | 콜라겐 비트리겔 및 이의 정제물의 제조 방법, 그리고 해당 방법에 의해 얻어진 콜라겐 비트리겔 및 이의 정제물 |
CN201880063452.0A CN111183152A (zh) | 2017-09-29 | 2018-07-09 | 胶原玻璃化凝胶及其精制物的制造方法以及通过该方法而得到的胶原玻璃化凝胶及其精制物 |
US16/650,413 US20210001005A1 (en) | 2017-09-29 | 2018-07-09 | Method for producing collagen vitrigel, method for producing purified collagen vitrigel, and collagen vitrigel and purified collagen vitrigel produced by said methods |
EP18862547.9A EP3689901A4 (en) | 2017-09-29 | 2018-07-09 | PROCESS FOR THE PRODUCTION OF VITRIGEL OF COLLAGEN, PROCESS FOR THE PRODUCTION OF VITRIGEL OF PURIFIED COLLAGEN AND VITRIGEL OF COLLAGEN AND VITRIGEL OF PURIFIED COLLAGEN PRODUCED BY THE SAID PROCESSES |
JP2019544303A JP6885551B2 (ja) | 2017-09-29 | 2018-07-09 | コラーゲンビトリゲル及びその精製物の製造方法並びに当該方法により得られたコラーゲンビトリゲル及びその精製物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017-189789 | 2017-09-29 | ||
JP2017189789 | 2017-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019064807A1 true WO2019064807A1 (ja) | 2019-04-04 |
Family
ID=65901477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/025846 WO2019064807A1 (ja) | 2017-09-29 | 2018-07-09 | コラーゲンビトリゲル及びその精製物の製造方法並びに当該方法により得られたコラーゲンビトリゲル及びその精製物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210001005A1 (ja) |
EP (1) | EP3689901A4 (ja) |
JP (1) | JP6885551B2 (ja) |
KR (1) | KR20200066314A (ja) |
CN (1) | CN111183152A (ja) |
WO (1) | WO2019064807A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022085377A1 (ja) * | 2020-10-19 | 2022-04-28 | 国立研究開発法人農業・食品産業技術総合研究機構 | 複合糸及びその使用 |
WO2022265021A1 (ja) * | 2021-06-15 | 2022-12-22 | 株式会社 資生堂 | アテロコラーゲンと毛球部毛根鞘(dsc)細胞とを含む組成物、毛髪を再生するためのキット、毛髪を再生するための組成物を製造する方法及び毛髪を再生する方法 |
JP7433627B2 (ja) | 2019-12-13 | 2024-02-20 | 祐徳薬品工業株式会社 | コラーゲンキセロゲル及びその製造方法並びにコラーゲンキセロゲルの安定化方法 |
JP7479663B2 (ja) | 2019-12-13 | 2024-05-09 | 祐徳薬品工業株式会社 | コラーゲンキセロゲル及びその製造方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4674211B2 (ja) | 2004-08-24 | 2011-04-20 | グンゼ株式会社 | 人工皮膚の製造方法 |
WO2012026531A1 (ja) * | 2010-08-25 | 2012-03-01 | 独立行政法人農業生物資源研究所 | ハイドロゲル乾燥体、ビトリゲル膜乾燥体およびこれらの製造方法 |
WO2016068228A1 (ja) * | 2014-10-29 | 2016-05-06 | 株式会社高研 | 薬剤徐放担体及び薬剤徐放方法 |
JP6071468B2 (ja) | 2012-11-22 | 2017-02-01 | 地方独立行政法人東京都立産業技術研究センター | コラーゲン水溶液及びそれから得られるゲル |
JP2017086066A (ja) * | 2015-11-05 | 2017-05-25 | 多木化学株式会社 | 線状コラーゲン架橋多孔体 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3081130B2 (ja) * | 1995-02-23 | 2000-08-28 | 科学技術振興事業団 | 細胞外マトリックス成分含有ハイドロゲル薄膜 |
JP3437430B2 (ja) * | 1997-12-27 | 2003-08-18 | 株式会社メニコン | コラーゲン成形体及びコラーゲン成形体の作製法 |
JP4677559B2 (ja) * | 2006-02-02 | 2011-04-27 | 財団法人ヒューマンサイエンス振興財団 | 任意の形状のビトリゲルと、当該ビトリゲルの製造方法 |
WO2011126294A2 (ko) * | 2010-04-06 | 2011-10-13 | 동국대학교 산학협력단 | 콜라겐 하이드로겔 제조용 멀티 시린지 |
JP6432967B2 (ja) * | 2014-05-12 | 2018-12-05 | 多木化学株式会社 | 溶解性コラーゲン線維多孔体 |
-
2018
- 2018-07-09 US US16/650,413 patent/US20210001005A1/en not_active Abandoned
- 2018-07-09 CN CN201880063452.0A patent/CN111183152A/zh active Pending
- 2018-07-09 KR KR1020207010563A patent/KR20200066314A/ko unknown
- 2018-07-09 JP JP2019544303A patent/JP6885551B2/ja active Active
- 2018-07-09 WO PCT/JP2018/025846 patent/WO2019064807A1/ja unknown
- 2018-07-09 EP EP18862547.9A patent/EP3689901A4/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4674211B2 (ja) | 2004-08-24 | 2011-04-20 | グンゼ株式会社 | 人工皮膚の製造方法 |
WO2012026531A1 (ja) * | 2010-08-25 | 2012-03-01 | 独立行政法人農業生物資源研究所 | ハイドロゲル乾燥体、ビトリゲル膜乾燥体およびこれらの製造方法 |
JP6071468B2 (ja) | 2012-11-22 | 2017-02-01 | 地方独立行政法人東京都立産業技術研究センター | コラーゲン水溶液及びそれから得られるゲル |
WO2016068228A1 (ja) * | 2014-10-29 | 2016-05-06 | 株式会社高研 | 薬剤徐放担体及び薬剤徐放方法 |
JP2017086066A (ja) * | 2015-11-05 | 2017-05-25 | 多木化学株式会社 | 線状コラーゲン架橋多孔体 |
Non-Patent Citations (8)
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7433627B2 (ja) | 2019-12-13 | 2024-02-20 | 祐徳薬品工業株式会社 | コラーゲンキセロゲル及びその製造方法並びにコラーゲンキセロゲルの安定化方法 |
JP7479663B2 (ja) | 2019-12-13 | 2024-05-09 | 祐徳薬品工業株式会社 | コラーゲンキセロゲル及びその製造方法 |
WO2022085377A1 (ja) * | 2020-10-19 | 2022-04-28 | 国立研究開発法人農業・食品産業技術総合研究機構 | 複合糸及びその使用 |
WO2022265021A1 (ja) * | 2021-06-15 | 2022-12-22 | 株式会社 資生堂 | アテロコラーゲンと毛球部毛根鞘(dsc)細胞とを含む組成物、毛髪を再生するためのキット、毛髪を再生するための組成物を製造する方法及び毛髪を再生する方法 |
Also Published As
Publication number | Publication date |
---|---|
US20210001005A1 (en) | 2021-01-07 |
JPWO2019064807A1 (ja) | 2020-08-13 |
EP3689901A1 (en) | 2020-08-05 |
JP6885551B2 (ja) | 2021-06-16 |
KR20200066314A (ko) | 2020-06-09 |
CN111183152A (zh) | 2020-05-19 |
EP3689901A4 (en) | 2021-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6885551B2 (ja) | コラーゲンビトリゲル及びその精製物の製造方法並びに当該方法により得られたコラーゲンビトリゲル及びその精製物 | |
JP6138370B2 (ja) | セリシンハイドロゲルの調製方法と使用 | |
US9315562B2 (en) | High-strength collagen fiber membrane and a manufacturing method thereof | |
El Blidi et al. | Extraction methods, characterization and biomedical applications of collagen: A review | |
Moisenovich et al. | Composite scaffolds containing silk fibroin, gelatin, and hydroxyapatite for bone tissue regeneration and 3D cell culturing | |
KR102146682B1 (ko) | 하이브리드 바이오 잉크와 그 제조 방법, 및 이를 이용한 인공 조직 제조 방법 | |
JPWO2005079879A1 (ja) | コラーゲンゲルおよびその製造方法 | |
KR20130027480A (ko) | 세포 지지체 및 골재생재 | |
JP2005334625A (ja) | 伸縮性コラーゲン成形体、その製造方法および用途 | |
US11439727B2 (en) | 3D printable bio gel and method of use | |
CN112980001B (zh) | 一种胶原蛋白复合透明质酸凝胶、细胞外基质仿生材料及制备方法 | |
US11369714B2 (en) | Method for producing collagen hydrogels | |
WO2021012677A1 (zh) | 一种仿生的预脉管化材料及其制备方法和应用 | |
CN108310463B (zh) | 一种3d打印生物墨水及其制备方法 | |
JP5453690B2 (ja) | コラーゲン・キトサン複合繊維状多孔体及びその製造方法 | |
CN108452378B (zh) | 一种3d生物打印成型方法 | |
JPH1147258A (ja) | ゼラチンとコラーゲンとを含有する医用基材 | |
Dong et al. | Electrospun nanofibrous membranes of recombinant human collagen type III promote cutaneous wound healing | |
US20200282107A1 (en) | Sterile clear concentrated solution of biocompatible collagen, process for the preparation and use thereof | |
EP1504774A1 (en) | Artificial extracellular matrix and process for producing the same | |
CN110624134A (zh) | 一种负载鹿茸多肽的ⅰ型/ⅲ型胶原软骨修复支架 | |
JP7479663B2 (ja) | コラーゲンキセロゲル及びその製造方法 | |
JP7433627B2 (ja) | コラーゲンキセロゲル及びその製造方法並びにコラーゲンキセロゲルの安定化方法 | |
Ehrlich et al. | Marine collagens | |
RU2353397C2 (ru) | Биорассасываемая коллагеновая матрица, способ ее получения и применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18862547 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019544303 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20207010563 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018862547 Country of ref document: EP Effective date: 20200429 |